GLP-1 and Ghrelin: Two Opposing Hormones That Together Control Your Appetite and Blood Sugar

GLP-1 and ghrelin act as a yin-and-yang pair — one rising after meals to boost insulin and suppress hunger, the other rising before meals to inhibit insulin and drive appetite — creating a coordinated system for metabolic control.

Yada, Toshihiko et al.·American journal of physiology. Cell physiology·2025·Moderate EvidenceReview
RPEP-14292ReviewModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Review of basic science and translational research on GLP-1, ghrelin, and insulin interactions across cellular, neural, and whole-organism levels
Participants
Review of basic science and translational research on GLP-1, ghrelin, and insulin interactions across cellular, neural, and whole-organism levels

What This Study Found

GLP-1 and ghrelin act as opposing regulators of the insulin system at three key levels: pancreatic beta cells (GLP-1 stimulates insulin release, ghrelin suppresses it), vagal afferent neurons, and hypothalamic arcuate nucleus neurons. Critically, their timing is complementary — ghrelin rises and acts before meals while GLP-1 rises and acts after meals. This preprandial/postprandial interplay with insulin creates an integrated circadian control system for appetite, blood sugar, and metabolism.

Key Numbers

How They Did This

Narrative review integrating evidence from cellular studies in pancreatic beta cells, neurophysiology of vagal afferents and hypothalamic arcuate nucleus neurons, and hormonal signaling research across animal and human studies.

Why This Research Matters

Understanding how GLP-1 and ghrelin work together — not just individually — explains why drugs targeting either hormone can have such broad metabolic effects. It also suggests that future therapies manipulating both pathways simultaneously could achieve more precise control of appetite and blood sugar.

The Bigger Picture

Drugs targeting GLP-1 (semaglutide, tirzepatide) are transforming obesity and diabetes treatment, while ghrelin-targeting drugs (like MK-677) are used to stimulate growth hormone. Understanding that these two peptide systems are fundamentally interconnected — not isolated pathways — could inform the next generation of metabolic drugs and explain why GLP-1 drugs affect so many aspects of metabolism beyond weight loss.

What This Study Doesn't Tell Us

As a review, this synthesizes existing research rather than presenting new data. Much of the mechanistic detail comes from animal models (particularly mice). The described interplay between GLP-1, ghrelin, and insulin is a framework for understanding, not a complete model — other hormones and neural pathways also participate.

Questions This Raises

  • ?Could drugs that simultaneously enhance GLP-1 signaling and suppress ghrelin produce even greater metabolic benefits than targeting either alone?
  • ?Does the disruption of ghrelin-GLP-1 circadian timing contribute to metabolic dysfunction in shift workers?
  • ?How does ghrelin resistance in obesity affect this reciprocal relationship with GLP-1?

Trust & Context

Key Stat:
3 sites of opposing action GLP-1 and ghrelin inversely regulate insulin at pancreatic beta cells, vagal afferents, and hypothalamic arcuate nucleus neurons
Evidence Grade:
Rated moderate because this review synthesizes well-established cellular and physiological research, but the integrated framework describing GLP-1/ghrelin interplay is partly theoretical and draws heavily on animal model data.
Study Age:
Published in 2025, this is a current review that integrates decades of research into a unified framework. Highly relevant given the surge of interest in GLP-1-based therapies.
Original Title:
GLP-1 and ghrelin inversely regulate insulin secretion and action in pancreatic islets, vagal afferents, and hypothalamus for controlling glycemia and feeding.
Published In:
American journal of physiology. Cell physiology, 328(6), C1793-C1807 (2025)
Database ID:
RPEP-14292

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

How do GLP-1 and ghrelin work together to control hunger?

They work as a tag team with opposite effects. Ghrelin rises before meals, signaling hunger and preparing your body for food by suppressing insulin. GLP-1 rises after meals, signaling fullness and boosting insulin to handle incoming nutrients. This pre-meal/post-meal rhythm helps coordinate when you eat and how your body processes food.

Why does this matter for understanding GLP-1 drugs like Ozempic?

GLP-1 drugs mimic one half of this natural hormonal balance. Understanding that GLP-1 normally works in opposition to ghrelin helps explain the drugs' broad effects — they don't just lower blood sugar, they shift the entire appetite-metabolism balance toward the 'fed and satisfied' state, which is why they reduce hunger so effectively.

Read More on RethinkPeptides

Cite This Study

RPEP-14292·https://rethinkpeptides.com/research/RPEP-14292

APA

Yada, Toshihiko; Dezaki, Katsuya; Iwasaki, Yusaku. (2025). GLP-1 and ghrelin inversely regulate insulin secretion and action in pancreatic islets, vagal afferents, and hypothalamus for controlling glycemia and feeding.. American journal of physiology. Cell physiology, 328(6), C1793-C1807. https://doi.org/10.1152/ajpcell.00168.2025

MLA

Yada, Toshihiko, et al. "GLP-1 and ghrelin inversely regulate insulin secretion and action in pancreatic islets, vagal afferents, and hypothalamus for controlling glycemia and feeding.." American journal of physiology. Cell physiology, 2025. https://doi.org/10.1152/ajpcell.00168.2025

RethinkPeptides

RethinkPeptides Research Database. "GLP-1 and ghrelin inversely regulate insulin secretion and a..." RPEP-14292. Retrieved from https://rethinkpeptides.com/research/yada-2025-glp1-and-ghrelin-inversely

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.